This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

29 Drugs Facing FDA Approval in 2012

Calendar updated to include several drug approvals inadvertently omitted.

BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012.

The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between May and December 2012. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst. The calendar was compiled with some assistance from BioMedTracker.com, a very useful database of experimental drug and drug-development catalysts compiled by Sagient Research.

Alexza Pharmaceuticals (ALXA)
Drug/indication: Adasuve for agitation related to schizophrenia
Approval decision date: May 4
A drug inhaled into the lungs, a split FDA advisory panel vote and lingering safety concerns make Adasuve's approval odds a tough call.

Regeneron Pharmaceuticals (REGN)
Drug/indication: Arcalyst for prevention of gout flares
FDA advisory panel date: May 8
Approval decision date: July 30
This will be the second approved indication for Arcalyst, which is currently marketed as a treatment for cryopyrin-associated periodic syndromes (CAPS).

Pfizer (PFE)
Drug/indication: Tofacitinib for rheumatoid arthritis
FDA advisory panel date: May 9
Approval decision date: August (exact date not specified)
Tofacitinib would be the first pill approved for the treatment of rheumatoid arthritis, competing with established injectable drugs like Abbbot's Humira.

Arena Pharmaceuticals (ARNA)
Drug/indication: Lorcaserin for obesity
FDA advisory panel date: May 10
Approval decision date: June 27
This is the second review cycle for lorcaserin.

Gilead Sciences (GILD)
Drug/indication: Quad for HIV
FDA advisory panel date: May 11
Approval decision date: Aug. 27
Quad combines four Gilead drugs into a single, once-daily pill for HIV. The new (and still experimental) components in the Quad are the integrase inhibitor elvitegravir and cobicistat, which is used to boost blood levels of elvitegravir.

Talon Therapeutics (TLON)
Drug/indication: Marqibo for advanced acute lymphoblastic leukemia
Approval decision date: May 13
In March, an FDA advisory panel voted to recommend approval of Marqibo.

Merck (MRK) and Ariad Pharmaceuticals (ARIA)
Drug/indication: Taltorvic for sarcoma
Approval decision date: June 5
In March, an FDA advisory panel recommended against approval of Taltorvic.

Roche (RHHBY)
Drug/indication: Pertuzumab for HER2-positive metastatic breast cancer
Approval decision date: June 8

Onyx Pharmaceuticals (ONXX)
Drug/indication: Carfilzomib for relapsed/refractory multiple myeloma
FDA advisory panel date: June 20
Approval decision date: July 27

Bristol-Myers Squibb (BMY) and Pfizer
Drug/indication: Eliquis for stroke prevention in patients with atrial fibrillation
Approval decision date: June 28
FDA delayed the Eliquis approval decision by three months.

Celgene (CELG)
Drug/indication: Revlimid in first-line multiple myeloma
European approval decision date: Second or third quarter
This calendar is focused on U.S. regulatory decisions, but Celgene's efforts to get Revlimid approved as a first-line treatment for multiple myeloma in Europe is crucial for the company's growth and stock price.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,757.16 +79.26 0.48%
S&P 500 1,959.64 +8.82 0.45%
NASDAQ 4,469.23 +16.4380 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs